IR-Med

Executive Summary

IR-Med Inc. is an Israeli medtech company developing a non-invasive infrared spectroscopy and AI platform for point-of-care biomarker profiling. Its handheld devices target pressure injuries, diabetic foot ulcers, therapeutic drug monitoring, and pediatric ear infections, with a skin-tone-agnostic design to ensure equitable diagnostic accuracy. The company is at a preclinical stage, focusing on technology validation and prototype refinement. IR-Med's platform has the potential to address critical diagnostic gaps in wound care, diabetes management, and infectious disease by providing real-time, non-invasive clinical decision support. While still early-stage, the company's multidisciplinary approach and unmet need across multiple indications offer a promising investment thesis, contingent on successful transition into clinical development and regulatory clearance.

Upcoming Catalysts (preview)

• Q2 2026Completion of First Human Pilot Study50% success
• Q4 2025Key Partnership with Hospital or Wound Care Center40% success
• Q1 2026US FDA Pre-Submission Meeting for Device Clearance Pathway60% success